Current Neurology and Neuroscience Reports

, 11:455

Role of Cerebrospinal Fluid and Plasma Biomarkers in the Diagnosis of Neurodegenerative Disorders and Mild Cognitive Impairment

  • Luis F. Gonzalez-Cuyar
  • Joshua A. Sonnen
  • Kathleen S. Montine
  • C. Dirk Keene
  • Thomas J. Montine
Article

DOI: 10.1007/s11910-011-0212-0

Cite this article as:
Gonzalez-Cuyar, L.F., Sonnen, J.A., Montine, K.S. et al. Curr Neurol Neurosci Rep (2011) 11: 455. doi:10.1007/s11910-011-0212-0
  • 121 Views

Abstract

Biomarkers are one type of laboratory testing being developed in response to the therapeutic imperative for diseases that cause cognitive impairment and dementia. The role of biomarkers is already transforming the organization and conduct of clinical trials, and if successful will likely contribute in the future to the medical management of patients with these diseases. Despite the obvious utility of practicality of blood- or urine-based biomarkers, so far results from these fluid compartments have not been reproducible. In contrast, substantial progress has been made in cerebrospinal fluid biomarkers. Here we review the stages of cerebrospinal fluid biomarker development for several common and unusual diseases that cause cognitive impairment and dementia, stressing the distinction between diagnostic and mechanistic biomarkers. Future applications will likely focus on diagnosis of latent or early-stage disease, assessment of disease progression, mechanism of injury, and response to experimental therapeutics.

Keywords

Alzheimer’s diseaseParkinson’s diseaseVascular brain injuryBiomarkersCerebrospinal fluidNeurodegenerative disordersMild cognitive impairment

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Luis F. Gonzalez-Cuyar
    • 1
  • Joshua A. Sonnen
    • 1
  • Kathleen S. Montine
    • 1
  • C. Dirk Keene
    • 1
  • Thomas J. Montine
    • 1
  1. 1.Department of PathologyUniversity of WashingtonSeattleUSA